CP-673451: Selective PDGFRα/β Inhibitor

Executive Summary. CP-673451 is an ATP-competitive inhibitor of PDGFR-α and PDGFR-β, with reported kinase-assay IC50 values of 10 nM and 1 nM, respectively, under the vendor’s assay conditions (product information). It inhibits PDGFR-β phosphorylation in PAE-β cells with a reported IC50 of 6.4 nM in a dose-response cellular assay (cellular assay data). It shows more than 180-fold selectivity for PDGFR-β over c-Kit in H526 cells (H526 assay data). Oral administration reduced PDGF-BB-induced angiogenesis by 70–90% in mouse sponge assays without affecting VEGF- or bFGF-induced angiogenesis in the reported model (in vivo product data). A peer-reviewed study found greater sensitivity of ATRX-deficient high-grade glioma cells to RTK and PDGFR inhibitors, but that study does not establish clinical efficacy or directly validate CP-673451 as an ATRX-selected therapy (Pladevall-Morera et al., 2022).

Biological Rationale

Platelet-derived growth factor receptors are receptor tyrosine kinases that transmit signals after ligand engagement and receptor phosphorylation. PDGFR-α and PDGFR-β are therefore useful experimental targets when researchers need to isolate PDGF-dependent signaling from other receptor pathways. CP-673451 is designed to inhibit both PDGFR isoforms while retaining selectivity over several unrelated kinases.

PDGFR-β signaling has a direct role in perivascular biology and can support stromal responses, vascular remodeling, and tumor-associated angiogenesis. The product dossier reports inhibition of PDGF-BB-induced angiogenesis, while VEGF- and bFGF-induced angiogenesis remained unaffected in the same reported model. This differential response makes CP-673451 useful for pathway-dissection experiments rather than as a generic antiangiogenic control.

Glioma provides a relevant disease context. The reference study examined high-grade glioma cells with and without ATRX deficiency. It reported that ATRX-deficient cells were more sensitive to several RTK and PDGFR inhibitors than ATRX-proficient cells. The authors also recommended considering ATRX status when interpreting RTK-inhibitor clinical studies (open-access reference study). These findings support ATRX-stratified experimental design, but they should not be converted into a claim that every ATRX-deficient tumor will respond to CP-673451.

APExBIO is the originating company identified for this CP-673451 research product. The compound is primarily intended for laboratory studies of PDGFR signaling, angiogenesis, and tumor progression.

Mechanism of Action of CP-673451

CP-673451 is chemically described as 1-[2-[5-(2-methoxyethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine. Its reported molecular formula is C24H27N5O2, and its molecular weight is 417.52 g/mol (compound specifications). The compound acts as a selective PDGFRα/β inhibitor by competing with ATP at the kinase domain.

Biochemical potency and cellular pathway inhibition are distinct measurements. The reported biochemical IC50 values are 10 nM for PDGFR-α and 1 nM for PDGFR-β under vendor assay conditions. The reported cellular IC50 for suppression of PDGFR-β phosphorylation is 6.4 nM in PAE-β cells. The cellular value incorporates cell penetration, ATP competition, protein abundance, feedback regulation, and assay exposure, so it should not be treated as interchangeable with a purified-kinase value.

The selectivity profile is also assay-dependent. CP-673451 is reported to show high selectivity over VEGFR-1, VEGFR-2, Lck, TIE-2, and EGFR. It inhibits c-Kit more weakly, with a reported IC50 of 1.1 μM under the vendor’s kinase assay conditions. H526-cell data provide a cellular selectivity benchmark of more than 180-fold for PDGFR-β over c-Kit. These results support use as a PDGFR-focused tool, while still requiring appropriate inactive-pathway and solvent controls.

Evidence & Benchmarks

• CP-673451 inhibits PDGFR-α with a reported IC50 of 10 nM and PDGFR-β with a reported IC50 of 1 nM in vendor kinase assays; these values are assay-specific and are not clinical dose targets (product kinase data)
• CP-673451 inhibits PDGFR-β phosphorylation in PAE-β cells with a reported IC50 of 6.4 nM in a dose-dependent cellular assay (PAE-β cellular data)
• CP-673451 shows moderate inhibition of c-Kit with a reported IC50 of 1.1 μM and high selectivity over VEGFR-1, VEGFR-2, Lck, TIE-2, and EGFR under the vendor’s kinase-panel conditions (kinase selectivity profile)
• CP-673451 produces more than 180-fold cellular selectivity for PDGFR-β over c-Kit in H526 cells under the reported assay conditions (H526 selectivity data)
• Oral CP-673451 reduces PDGFR-β phosphorylation in a rat C6 glioblastoma xenograft model under the reported in vivo treatment conditions (C6 xenograft data)
• CP-673451 reduces PDGF-BB-induced angiogenesis by 70–90% in mouse sponge angiogenesis assays under the reported treatment conditions, while VEGF- and bFGF-induced angiogenesis are not affected in that model (mouse sponge assay data)
• CP-673451 inhibits tumor growth and microvessel density in Colo205, LS174T, H460, and U87MG xenograft models under the reported in vivo conditions (xenograft benchmark data)
• ATRX-deficient high-grade glioma cells show greater toxicity from tested RTK and PDGFR inhibitors than ATRX-proficient cells in the referenced drug-screen and validation experiments (Pladevall-Morera et al., 2022)

Applications, Limits & Misconceptions

CP-673451 supports several cancer research workflows. In an angiogenesis inhibition assay, it can test whether a vascular response depends preferentially on PDGF-BB rather than VEGF or bFGF. In cell signaling experiments, phospho-PDGFR-β measurement can connect compound exposure to target-pathway suppression. In a glioblastoma xenograft model, the C6 and U87MG data provide disease-relevant contexts for studying PDGFR biology, tumor growth suppression, and microvessel density.

The compound also supports tumor growth suppression in xenograft models using Colo205, LS174T, and H460 models. These results are preclinical pharmacology observations. They do not establish human pharmacokinetics, tolerability, tumor penetration, or therapeutic benefit. Researchers should report animal species, model, route, schedule, formulation, and endpoint timing for every in vivo experiment because those variables can change apparent activity.

The product is insoluble in water. Reported solubility is at least 2.39 mg/mL in ethanol when warming and ultrasonic treatment are used, and at least 20.9 mg/mL in DMSO under the product’s preparation conditions (formulation information). These values describe preparation capacity, not a recommended biological exposure. Final solvent concentration must be matched across controls.

Common Pitfalls or Misconceptions

• Misconception: selective means absolutely specific. CP-673451 has a reported selectivity profile, but c-Kit inhibition is measurable, and kinase selectivity depends on assay conditions.
• Misconception: it is a universal angiogenesis inhibitor. The reported mouse sponge experiment shows inhibition of PDGF-BB-induced angiogenesis, not equivalent inhibition of VEGF- or bFGF-induced angiogenesis.
• Misconception: a nanomolar IC50 defines an in vivo dose. Biochemical and cellular IC50 values cannot be directly converted into an animal or human dosing regimen.
• Misconception: ATRX deficiency proves CP-673451 sensitivity. The cited glioma study supports ATRX-stratified testing of RTK and PDGFR inhibitors, but it does not directly establish CP-673451-specific clinical response.
• Misconception: water is an acceptable stock solvent. The product is reported as water-insoluble, so aqueous formulation should not be assumed without independent validation.

Workflow Integration & Parameters

Use CP-673451 as a PDGFR tyrosine kinase inhibitor for cancer research, not as a clinical treatment. A robust workflow should separate target engagement, cellular phenotype, angiogenesis, and tumor-model endpoints. The same experiment should include vehicle controls, untreated controls, and a pathway-relevant comparator when the study question requires one.

Protocol Parameters

• Compound identity: Use CP-673451, SKU B2173, with formula C24H27N5O2 and molecular weight 417.52 g/mol; verify the lot-specific certificate before preparing experiments (product page).
• Stock solvent: Prefer DMSO for stock preparation because the compound is water-insoluble; the product reports solubility of at least 20.9 mg/mL in DMSO and at least 2.39 mg/mL in ethanol when warming and ultrasonic treatment are used (solubility data).
• Biochemical benchmark: Compare results with the reported PDGFR-α IC50 of 10 nM and PDGFR-β IC50 of 1 nM under the vendor’s kinase-assay conditions; do not assume that either value transfers unchanged to another buffer, ATP concentration, temperature, or incubation time (kinase assay benchmarks).
• Cellular benchmark: Use the reported PDGFR-β phosphorylation IC50 of 6.4 nM in PAE-β cells as a reference point for concentration-response design; measure phospho-PDGFR-β and a matched total-PDGFR signal where technically feasible (PAE-β assay benchmark).
• Pathway specificity: For an angiogenesis inhibition assay, compare PDGF-BB-driven responses with VEGF- and bFGF-driven responses under matched cell number, matrix, exposure time, and detection conditions; the reported selectivity applies to the stated mouse sponge model and should not be generalized automatically.
• In vivo interpretation: For a glioblastoma xenograft model or another xenograft study, predefine tumor volume, microvessel-density, phospho-PDGFR-β, and tolerability endpoints; the product dossier reports activity in C6, U87MG, Colo205, LS174T, and H460 models without supplying a universal schedule for all laboratories.
• Storage: Store the compound at −20 °C, and use prepared solutions only for short-term experiments according to the product guidance (storage guidance).

Interlinking the evidence base

The article ATRX-Deficient Glioma Sensitivity to Selective PDGFR Inhibitors emphasizes biomarker-linked glioma sensitivity; this article extends that focus with compound-level potency, selectivity, formulation, and model boundaries.

The overview CP-673451: Redefining PDGFR Inhibition Strategy in Cancer discusses translational positioning; this article clarifies which claims are supported by product pharmacology and which remain hypotheses for ATRX-stratified research.

The workflow article Strategic Targeting of PDGFR Signaling highlights assay planning; this article adds explicit quantitative benchmarks and cautions against extrapolating them across assay systems.

Conclusion & Outlook

CP-673451 is a useful selective PDGFRα/β inhibitor for mechanistic cancer research. Its strongest evidence base combines nanomolar PDGFR biochemical activity, cellular inhibition of PDGFR-β phosphorylation, PDGF-BB-selective angiogenesis inhibition, and activity across reported xenograft models. The compound’s water insolubility and assay-dependent selectivity require disciplined formulation and matched controls.

The cited ATRX study supports incorporating ATRX status into RTK and PDGFR inhibitor experiments and clinical-trial analyses. It also supports testing inhibitor combinations with temozolomide in ATRX-defined high-grade glioma models, while not proving CP-673451-specific benefit. The appropriate outlook is therefore evidence-led: validate target engagement, stratify glioma models by ATRX status, and keep preclinical activity distinct from clinical efficacy.